This task force was established through the collaboration of five international organizations—ECNP, ACNP, AsCNP, CINP, and IUPHAR—to integrate recent advances in neuroscience into psychopharmacological nomenclature.
Members of the task force include several prominent experts, such as Professor Joseph Zohar (Chair), Professor Stephen Stahl, Professor Pierre Blier, Professor Hiroyuki Uchida, and Professor Hans-Jürgen Möller.
The primary mission of this task force is to modernize the nomenclature for medications used in the treatment of central nervous system (CNS) disorders. This updated nomenclature will guide clinicians in making more informed neuropsychopharmacological decisions. The current system of categorizing psychotropic medications often fails to reflect contemporary neuroscience, leaving clinicians with outdated guidance. For example, medications labeled as "antidepressants" are frequently prescribed for anxiety disorders, and "second-generation antipsychotics" are commonly used to treat depression—practices that do not align with current neuroscientific understanding.
The task force has been entrusted with delivering three key products: a pharmacologically driven, neuroscience-based nomenclature for psychotropic medications; a similar framework tailored for child and adolescent psychotropics; and a version of the nomenclature adapted for patients and their families.
For more information, please visit: https://www.nbn.science.
